Radiopharm Theranostics Limited

As of December 31, 2024, Radiopharm Theranostics Limited carries a market capitalization of 52.82M, placing it among publicly traded companies globally. Its enterprise value stands at 15.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Radiopharm Theranostics Limited's next confirmed earnings release is scheduled for February 26, 2027.

As of December 31, 2024, Radiopharm Theranostics Limited has 2.20B shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Radiopharm Theranostics Limited maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Radiopharm Theranostics Limited's stock has declined approximately 84.62% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

These figures are as of December 31, 2024. Total book value stands at 53.20M, with working capital of 31.21M providing operational flexibility.

These figures cover the twelve months ended December 31, 2024. Total shareholder yield is negative at -122.28, meaning Radiopharm Theranostics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Radiopharm Theranostics Limited's most recent stock split took place on November 2, 2023 with a 17:18 split ratio.